MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinomaAnkit Jain(Institute of Bioinformatics), Harsha Gowda(Yenepoya University)Scientific ReportsDecember 11, 201910.1038/s41598-019-55208-5Cited by 21SaveCiteExport RISWatch citationsRelated PapersPhosphotyrosine profiling identifies ephrin receptor A2 as a potential therapeutic target in esophageal squamous‐cell carcinoma|PROTEOMICS|2014|23Temporal Quantitative Proteomics Reveals Proteomic and Phosphoproteomic Alterations Associated with Adaptive Response to Hypoxia in Melanoma Cells|Cancers|2021|9Identification of spleen tyrosine kinase as a potential therapeutic target for esophageal squamous cell carcinoma using reverse phase protein arrays|Oncotarget|2018|5